autologous anti-CD19 CAR-T cells CABA-201

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-lymphocyte antigen CD19, coupled to a costimulatory domain of 4-1BB (CD137), with potential immunomodulatory activity. Upon administration, autologous anti-CD19 CAR-T cells CABA-201 target and bind to CD19-expressing B cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing B cells. CD19, a B-cell-specific cell surface antigen that plays an important role in B-cell activation, is overexpressed in some autoimmune diseases.